Stock comparison
Praxis Precision Medicines
Summit Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
PRAX
Praxis Precision Medicines
Market cap
$7.24B
Sector
Healthcare
SMMT
Summit Therapeutics
Market cap
$13.08B
Sector
Healthcare
Overall winner
Summit Therapeutics SMMT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | PRAX | SMMT | Winner |
|---|---|---|---|
| Warren Buffett | 19F | 12F | PRAX |
| Benjamin Graham | 40D | 40D | Tie |
| Philip Fisher | 30F | 38D | SMMT |
| Peter Lynch | 10F | 64C | SMMT |
| Joel Greenblatt | 0F | 0F | Tie |
| Charlie Munger | 23F | 15F | PRAX |
| Terry Smith | 28F | 15F | PRAX |
Side-by-side metrics
| Metric | PRAX | SMMT |
|---|---|---|
| Market cap | $7.24B | $13.08B |
| P/E (TTM) | - | - |
| EV/EBIT | - | - |
| ROIC (TTM) | -25.32% | -2.48% |
| Gross margin | 0.0% | 0.0% |
| Net margin | 0.0% | 0.0% |
| Revenue CAGR 5y | - | - |
| EPS CAGR 5y | - | 39.68% |
| Debt / Equity | 0.0x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
PRAX leads on
- Debt / Equity0.0xvs 0.0x+97%
- ROIC (TTM)-25.32%vs -2.48%+90%
- P/E (TTM)-vs -+59%
- EV/EBIT-vs -+42%
SMMT leads on
- Market cap$13.08Bvs $7.24B+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.